WaveMan
WaveMan · Company
PACB · Pacific Biosciences Of California, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PACB Pacific Biosciences of California (PACB) Insider Trading, Ownership & Congress Trades

Medical Devices · Laboratory analytical instruments · CIK 0001299130
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
94
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $590.0K priced

What the filings say about PACB

Insiders, 180 days
-$2.1M net sold
2 sellers · 50% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.9M
2 notices

Pacific Biosciences of California insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. insiders sold a net $2.1M of stock across 66 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Gibson James R II
See Remarks
SELL
2026-10-08 SECtraded 2026-10-06
661,815
$2.1M
-3.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 1, 2026.
  • The trade is 61.1% of the 1,083,848 shares held after it.
  • No other insider sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Gibson James R II sold about $2.1M of PACB under a 10b5-1 plan on Oct 6, 2026, the largest insider sale at the company since 2021; 94 funds added in the latest 13F quarter.
Van Oene Mark
See Remarks
SELL
2026-08-18 SECtraded 2026-08-17
26,911
$30.4K
+77.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Mar 3, 2026.
  • The trade is 1.0% of the 2,705,853 shares held after it.
  • No other insider sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Van Oene Mark sold about $30.4K of PACB on Aug 17, 2026; 94 funds added in the latest 13F quarter.
Gibson James R II
See Remarks
SELL
2026-04-03 SECtraded 2026-04-01
88,185
$120.8K
+58.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 7.1% of the 1,245,663 shares held after it.
  • 3 other insiders sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Gibson James R II sold about $120.8K of PACB on Apr 1, 2026; 3 other insiders sold within 30 days and 94 funds added in the latest 13F quarter.
HENRY CHRISTIAN O
See Remarks
SELL
2026-03-04 SECtraded 2026-03-03
12,497
$18.9K
+48.0%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Feb 18, 2026.
  • The trade is 0.3% of the 3,581,813 shares held after it.
  • 3 other insiders sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks HENRY CHRISTIAN O sold about $18.9K of PACB on Mar 3, 2026; 3 other insiders sold within 30 days and 94 funds added in the latest 13F quarter.
Van Oene Mark
See Remarks
SELL
2026-03-04 SECtraded 2026-03-03
6,504
$9.8K
+48.0%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Feb 18, 2026.
  • The trade is 0.3% of the 2,243,634 shares held after it.
  • 3 other insiders sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Van Oene Mark sold about $9.8K of PACB on Mar 3, 2026; 3 other insiders sold within 30 days and 94 funds added in the latest 13F quarter.
66 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 61 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.1M over 180 days
-$2.1M over 90 days
below 69% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
94 funds bought in last quarter
more than 62% of Medical Devices
Revenue
+3.9% year over year
below 69% of Medical Devices
Margin
-341.5% net margin
below 90% of Medical Devices
Buybacks
no share repurchases reported
Short interest
15.5% of the float short (float per yahoo 2026-10-26) · 3.0 days to cover · settled 2026-09-30
more than 96% of Medical Devices
What changed in the last 30 days
Oct 8See Remarks Gibson James R II sold $2.1M under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Officer Jim Gibson filed to sell $1.9M by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch PACB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+15.4%12M
-43%-13%+17%+47%2025-102025-122026-022026-042026-062026-082026-10 2026-10-06 · Gibson James R II sold $2.1M2026-02-17 · HENRY CHRISTIAN O sold $524.2K2026-02-18 · HENRY CHRISTIAN O sold $229.6K2026-02-17 · Van Oene Mark sold $205.1K2026-04-01 · Gibson James R II sold $120.8K2026-02-18 · Van Oene Mark sold $89.8K2026-02-17 · Farmer Michele sold $55.6K2026-08-17 · Van Oene Mark sold $30.4K2026-02-18 · Farmer Michele sold $24.4K2026-03-03 · HENRY CHRISTIAN O sold $18.9K2026-03-03 · Van Oene Mark sold $9.8K2026-03-03 · Farmer Michele sold $4.5K2026-10-06 · Jim Gibson filed to sell $1.9M2026-08-17 · MARK VAN OENE filed to sell $30.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PACB: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
32,339,550 sh
$54.3M
ARK Investment Management LLC
29,781,416 sh
$50.0M
SOFTBANK GROUP CORP.
20,451,570 sh
$34.4M
VANGUARD CAPITAL MANAGEMENT LLC
13,397,934 sh
$22.5M
GEODE CAPITAL MANAGEMENT, LLC
7,606,518 sh
$12.8M

Congress trades in PACB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PACB planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Jim Gibson
Filed 2026-10-06
$1.9M
MARK VAN OENE
Filed 2026-08-17
$30.5K

PACB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$14.9M position · as of 2026-07-31
1.0%
AltShares Event-Driven ETF
$92.4K position · as of 2026-05-31
0.8%
Water Island Event-Driven Fund
$338.3K position · as of 2026-05-31
0.7%
iShares Genomics Immunology and Healthcare ETF
$870.9K position · as of 2026-07-31
0.5%
Global X Genomics & Biotechnology ETF
$225.6K position · as of 2026-05-31
0.4%
Invesco NASDAQ Future Gen 200 ETF
$68.1K position · as of 2026-05-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.1M sold by insiders over 180 days, 94 funds added last quarter, $1.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

PACB financials

Revenue growth
+3.9%
XBRL, annual
Net margin
-341.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$159.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-82.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$123.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.13x
TTM operating cash flow over long-term 2023-03-31 (39 months older than the period end) plus current 2024-12-31 (18 months older than the period end)
Return on equity
-929.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-16.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-18.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.5B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2023-03-31 (39 months older than the period end) plus current 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
FCF yield
-17.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$160.0M$154.0M$200.5M$128.3M
Gross profit$45.8M$37.3M$52.8M$49.0M
Operating income-$553.9M-$474.3M-$334.5M-$307.2M
Net income-$546.4M-$309.9M-$306.7M-$314.2M
EPS (diluted)-1.82-1.59-1.21-1.40
Operating cash flow-$111.2M-$206.1M-$259.2M-$263.2M
Cash$63.7M$55.4M$179.9M$325.1M
Long-term debtn/an/an/a$896.7M
SEC XBRL, fiscal years, as known on 2026-10-28

PACB Stock Sonar score 6/7 axes

Find similar shapesCompare

PACB ranks highest on institutional and government (62nd percentile) and risk and compliance (56th), and lowest on growth (23rd), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
33
Inputs
  • Return on equity-929.5% · 3 pct, sector of 183
  • Return on assets-16.7% · 48 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-18.4% · 48 pct, sector of 188
Financial health
49
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.13x · 49 pct, sector of 150
Growth
23
Inputs
  • Revenue growth, YoY+3.9% · 31 pct, sector of 219
  • Backlog growth, YoY-15.4% · 14 pct, sector of 37
Insider conviction
28
Inputs
  • Net Form 4 buying (codes P and S), 180d-$30K · 57 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
62
Inputs
  • Funds adding, latest quarter94 · 62 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
56
Inputs
  • Short interest, % of float+15.5% · 8 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+8.5% · 61 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PACB filings, in plain words

Are Pacific Biosciences of California insiders buying or selling PACB?

In the 180 days to 2026-10-28, Pacific Biosciences of California insiders were net sellers, a net $2.1M across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of PACB?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.9M of stock; the latest, by Jim Gibson, was filed 2026-10-06.

Read the full summary

In the 180 days to 2026-10-28, Pacific Biosciences of California insiders were net sellers of PACB, a net $2.1M across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies